Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc Reaffirms FY 2012 Revenue And EBITDA Guidance; Raises FY 2012 Net Income Guidance


Thursday, 25 Oct 2012 04:00pm EDT 

Biomarin Pharmaceutical Inc announced that for fiscal 2012, it expects total revenue in the range of $ $475-$510 million, GAAP Net (Loss) in the range of $(100)-$(110) million and Non-GAAP Adjusted EBITDA in the range of $(5)-$5 million. The guidance for revenue and Non-GAAP Adjusted EBITDA is unchanged from prior guidance range. Prior guidance for GAAP Net (Loss) was in the range of $(105)-$(115) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $496 million and net income of $(103) million for fiscal 2012. 

Related Company News

Company Quote

70.4
-0.01 -0.01%
2 Oct 2014